Search results
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed...
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings...
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy...
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the...
Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for Clovis Oncology (CLVS). Shares have lost...
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
Zacks via Yahoo Finance· 2 years agoClovis Oncology, Inc.’s CLVS shares have plunged 49.6% in the past six months against the industry’s...
Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion...
The Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Have Been Trimming Their Sales Forecasts
Simply Wall St. via Yahoo Finance· 2 years agoToday is shaping up negative for Clovis Oncology, Inc. (NASDAQ:CLVS) shareholders, with the analysts...
Clovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 2 years agoClovis Oncology (NASDAQ:CLVS) Third Quarter 2022 ResultsKey Financial Results Revenue: US$30.7m...
Why Clovis Oncology Zoomed 30% Higher Today
Motley Fool· 2 years agoCancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a...